

Genome-Wide CpG Island Profiling of Intraductal Papillary Mucinous Neoplasms of the Pancreas

Seung-Mo Hong¹, Noriyuki Omura¹, Audrey Vincent¹, Ang Li¹, Spencer Knight¹, Jun Yu¹, Ralph H. Hruban^{1,3}, and Michael Goggins^{1,2,3}

Abstract

Purpose: Intraductal papillary mucinous neoplasms (IPMN) are precursors to infiltrating pancreatic ductal adenocarcinomas. Widespread epigenetic alterations are characteristic of many cancers, yet few studies have systematically analyzed epigenetic alterations of neoplastic precursors. Our goal was to conduct genome-wide CpG island methylation profiling to identify aberrantly methylated loci in IPMNs.

Experimental Design: We compared the CpG island methylation profiles of six IPMNs to normal primary pancreatic duct samples using methylation CpG island amplification (MCA) and Agilent CpG island microarray (MCAM) analysis. When selected 13 genes identified as differentially methylated by MCAM for methylation-specific PCR (MSP) analysis in an independent set of IPMNs and normal pancreas samples and conducted expression analysis of selected genes.

Results: We identified 2,259 loci as differentially methylated in at least one of six IPMNs including 245 genes hypermethylated in IPMNs with high-grade dysplasia compared with normal pancreatic duct samples. Eleven of 13 genes evaluated by MSP were more commonly methylated in 61 IPMNs than in 43 normal pancreas samples. Several genes (*BNIP3*, *PTCHD2*, *SOX17*, *NXPH1*, *EBF3*) were significantly more likely to be methylated in IPMNs with high-grade than with low-grade dysplasia. One gene, *SOX17*, showed loss of protein expression by immunohistochemistry in 22% (19 of 88) of IPMNs. The most specific marker, *BNIP3*, was not methylated in any IPMNs with low-grade dysplasia or in normal pancreas samples.

Conclusions: IPMNs undergo extensive aberrant CpG island hypermethylation. The detection of genes selectively methylated in high-grade IPMNs such as *BNIP3* may have use in the clinical evaluation of IPMNs. *Clin Cancer Res*; 18(3); 700–12. ©2011 AACR.

Introduction

Pancreatic cancer is the fourth leading cause of cancer death in the United States. In 2011, it is estimated that 44,030 Americans will be diagnosed and 37,660 patients will die of pancreatic cancer (1). The 5-year survival rate for patients with all stages of infiltrating pancreatic ductal adenocarcinomas is only about 6% and is only about 23% for patients whose disease is detected early enough to undergo surgical resection with curative intent (1). Detecting early-stage pancreatic cancer and its precursors by screening high-risk individuals is currently considered the best way to improve patient survival (2, 3). Intraductal

papillary mucinous neoplasms (IPMN) arise in the pancreatic ductal system and are distinct mucin-producing cystic precursor lesions of pancreatic ductal adenocarcinomas. IPMNs are large enough (usually more than 1 cm) to be detected by clinical imaging tests (4), unlike pancreatic intraepithelial neoplasias (PanIN), which are lesions of less than 5 mm (5). With the increasing use of abdominal imaging, IPMNs are commonly detected as incidental lesions (6).

Many of the molecular alterations of pancreatic ductal adenocarcinomas (reviewed in ref. 7) have been identified in IPMNs (8–10). Thus, the prevalence of *KRAS2* mutations increases in parallel with degree of dysplasia of IPMNs and have been detected in about 80% and *TP53* mutations in about 50% of IPMNs (11) with high-grade dysplasia. In addition, somatic mutations of the *STK11/LKB1* (12) and *PIK3CA* genes (13) have been identified in about 10% of IPMNs. A low prevalence of chromosomal losses have also been identified in IPMNs (14). Compared with PanINs and pancreatic ductal adenocarcinomas, IPMNs rarely show inactivation of *DPC4/SMAD4* even in high-grade lesions (15, 16).

Although genome-wide analyses of aberrant DNA methylation of pancreatic ductal adenocarcinomas have been

Authors' Affiliations: Departments of ¹Pathology, ²Medicine, and ³Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Corresponding Author: Michael Goggins, The Johns Hopkins Medical Institutions, 1550 Orleans Street, CRB2, Room 342, Baltimore, MD 21231. Phone: 410-955-3511; Fax: 410-614-0671; E-mail: mgoggins@jhmi.edu

doi: 10.1158/1078-0432.CCR-11-1718

©2011 American Association for Cancer Research.

Translational Relevance

Pancreatic cancer is the fourth leading cause of cancer death in the United States. Intraductal papillary mucinous neoplasms (IPMN) are an important precursor to pancreatic adenocarcinoma. They are commonly detected as asymptomatic lesions during abdominal scanning and pancreatic screening of individuals at high risk of developing pancreatic cancer. Most IPMNs are first detected as small lesions of low malignant potential necessitating regular imaging until their IPMN has features suggesting progression to adenocarcinoma. Molecular marker analysis of IPMNs to identify high-grade dysplasia and invasive cancer would permit optimal timing for surgical resection of IPMNs. In addition, a better understanding of molecular mechanisms that arise in pancreatic cancer precursors would improve our understanding of pancreatic cancer biology. In this study, we describe the first genome-wide analysis of IPMNs and identify hundreds of aberrantly hypermethylated genes in IPMNs and identify several genes such as *BNIP3* whose hypermethylation is highly specific for high-grade IPMNs.

described (17–21), no such DNA methylation analyses have been reported for IPMNs. Candidate gene analysis of genes methylated in pancreatic and other cancers has been conducted in IPMNs revealing that several genes including *CDKN1C/p57KIP2*, *CDKN2A/p16*, *PENK*, *SOCS-1*, *RELN*, *TFPI2*, *SPARC*, and others undergo aberrant methylation often associated with gene silencing (12, 18, 20, 22–24).

Genome-wide DNA methylation analysis of IPMNs has the potential not only to identify genes targeted in IPMNs but also to provide a better understanding of the timing of aberrant methylation events during pancreatic tumorigenesis, thereby helping to elucidate the DNA methylation events important for tumor development. In this study, we used methylated CpG island amplification (MCA) coupled with genome-wide CpG island microarrays (MCAM) followed by validation by methylation-specific PCR (MSP) to identify differentially methylated genes in IPMNs.

Materials and Methods

An overview of the experimental approach that we used in this study is summarized in Fig. 1.

Cell lines

Fourteen human pancreatic cancer cell lines, including A32-1, A38-5, BxPC3, Capan1, Capan2, CFPAC1, FamPanc, Miapaca2, Panc-1, Panc1.28, Panc2.5, PL4, PL8, and Su8686, were also used. An immortalized cell line derived from normal human pancreatic ductal epithelium (HPDE) was generously provided by Dr. Ming-Sound Tsao (University of Toronto, Toronto, ON, Canada).

Patients and tissues

Tissues were obtained for methylation analysis and immunohistochemistry and from patients with IPMNs as well as from patients with pancreatic ductal adenocarcinoma and from disease controls. A summary of the demographics of the patients and their tissues used in this study is provided in Table 1 and Supplementary Table S1. Fresh-frozen sections from 61 IPMNs and 10 invasive ductal adenocarcinomas with an associated IPMN were collected from 71 patients who underwent surgical resection of their neoplasm at the Johns Hopkins Medical Institutions, Baltimore, MD, from 1999 to 2008. These patient samples were selected on the basis of the availability of stored tissues with sufficient numbers of neoplastic cells for DNA methylation analysis. Fresh-frozen normal pancreatic tissues were obtained from 35 patients with ductal neoplasms (5 with IPMNs and 30 with an associated invasive pancreatic ductal adenocarcinomas) and 8 patients with benign pancreatic neuroendocrine neoplasms and used as control samples. Hematoxylin and eosin staining of frozen sections was conducted to assess the degree of dysplasia using criteria described elsewhere (25–28). The IPMNs were classified by their grade of dysplasia using the new WHO classification into low-, intermediate-, or high-grade dysplasia (29). IPMNs were also classified by their histologic subtype and localization of each IPMN as described elsewhere (26).

Formalin-fixed, paraffin-embedded IPMN tissues were additionally retrieved from 88 patients, 75 of these cases were used to create tissue microarrays for immunohistochemical labeling. In addition, tissue microarrays of formalin-fixed, paraffin-embedded pancreatic ductal adenocarcinoma tissues from 111 patients who underwent surgical resection of the pancreas at our institution were also analyzed by immunohistochemistry. All specimens were collected and analyzed with the approval of the Johns Hopkins Committee for Clinical Investigation.

IPMNs were carefully manually microdissected from frozen sections to collect neoplastic cells. Normal




Figure 1. An overview of the experimental approach used to evaluate differential DNA methylation in IPMNs.

Table 1. Clinicopathologic characteristics of patients with IPMNs

| Parameter | (%) |
|---------------------------------|-------------|
| Age (mean ± SD) | 68.5 ± 10.5 |
| Sex | |
| Male | 34 (52) |
| Female | 31 (48) |
| Age (mean ± SD), y | 68.5 ± 10.4 |
| Ethnicity | |
| Caucasian | 59 (90) |
| African American | 3 (5) |
| Other | 3 (5) |
| Association with adenocarcinoma | |
| Yes | 10 (15) |
| No | 55 (85) |
| Degree of dysplasia | |
| IPMN, low-grade dysplasia | 14 (22) |
| IPMN, intermediate dysplasia | 19 (29) |
| IPMN, high-grade dysplasia | 32 (49) |
| Tumor location | |
| Main duct | 43 (66) |
| Branch duct | 17 (26) |
| Unknown | 5 (8) |
| Histologic subtype | |
| Gastric | 23 (35) |
| Intestinal | 13 (20) |
| Pancreatobiliary | 29 (45) |

pancreatic ductal epithelial cells were selectively microdissected from frozen sections adjacent to IPMN, pancreatic ductal adenocarcinoma, or well-differentiated pancreatic neuroendocrine tumors using the PALM Micro Laser System (Carl Zeiss Microimaging Inc.).

DNA extraction

Genomic DNA was extracted from the microdissected samples with QIAamp DNA Micro Kit (Qiagen, Inc.) following the manufacturer's protocol. Extracted DNA was quantified by either Quantifiler (Applied Biosystems) or PicoGreen Assay (Invitrogen).

MCA

MCA was conducted on DNA from 6 IPMNs (1 IPMN with low-grade, 3 intermediate-grade, and 2 with high-grade dysplasia) and DNA from matched normal pancreatic samples as previously described with minor modifications (30). In brief, 500 ng of DNA was digested with *SmaI* and *XmaI* (New England Biolabs, Inc.). Unmethylated *SmaI* sites are eliminated by *SmaI* digestion, which leaves a blunt end fragment. In contrast, CCGGG sites with methylated CpG are not cut by *SmaI*. These methylated *SmaI* sites can then be digested with *XmaI*, which is the non-methylation-sensitive *SmaI* isoschizomer, leaving a CCGG overhanging sticky end. Adaptors are ligated to these sticky ends, and PCR is carried out to amplify the

methylated sequences. Restriction fragments were ligated to an RMCA adaptor and amplified by PCR in a 100 μ L volume containing 200 pmol of RMCA 24-mer primer, 600 mmol/L Tris-SO₄, 2 mmol/L MgSO₄, 160 mmol/L (NH₄)₂SO₄, 200 μ mol/L each dNTP, 2% (v/v) dimethyl sulfoxide, 0.5 mol/L betaine, and 2 U of Platinum Taq Hifidelity polymerase (Invitrogen). The reaction mixture was incubated at 72°C for 5 minutes and at 95°C for 3 minutes and then subjected to 25 cycles of 1 minute at 95°C and 3 minutes at 77°C followed by a final extension of 10 minutes at 77°C.

Agilent 244K human promoter and CpG island microarrays

Agilent's 244K Human promoter chip-on-chip microarray contains 195K CpG island probes and 50K non-CpG island probes and interrogates 27,800 CpG islands covering 21 MB with an average of 8 probes per island. Array hybridization was conducted by the Sidney Kimmel Cancer Center Microarray Core Facility at Johns Hopkins. Briefly, 2 μ g of MCA amplicon was labeled with either Cy3-dUTP or Cy5-dUTP (Perkin Elmer) by using BioPrime DNA Labeling System (Invitrogen). These dye-labeled amplicons were then mixed and co-hybridized to each of the 244K human promoter Chip on-chip microarrays. After the hybridization, the microarray slides were washed, dried, and scanned using an Agilent G2505B scanner.

Data were extracted with Agilent Feature Extraction 9.1 software. Methylation-specific sites were called with Agilent Genomic Workbench Standard Edition 5.0.14 software for methylation (CH3) analysis, which calculates the normalized log₂-signal ratios (NLR) and combined Z-scores for each probe. The cutoff value of 4-fold differential methylation [NLR >2 or <-2], which was validated previously (30), was used to identify differentially methylated probes in IPMN DNA relative to normal pancreatic duct DNA.

Methylated gene patterns were analyzed for evidence of associated gene network and pathway analysis using Ingenuity Pathways Analysis (Ingenuity Systems; <http://www.ingenuity.com>) software.

Bisulfite treatment of DNA

Microdissected DNA was treated by sodium bisulfite (Sigma-Aldrich) for 3 hours at 50°C as previously described (31). The bisulfite DNA was purified with Wizard DNA clean up system (Promega).

Bisulfite sequencing

The methylation status of the 5' CpG islands of *PCDH17* and *SOX17* was determined by bisulfite sequencing as described previously (30). Thirty nanograms of bisulfite-treated DNA in 3 μ L was amplified by PCR with RDA buffer. PCR conditions were as follows: (i) 95°C for 5 minutes; (ii) 45 cycles of 95°C for 20 seconds, 62°C for 20 seconds, and 72°C for 30 seconds; and (iii) a final extension of 4 minutes at 72°C. Amplicons were purified with the QIAquick PCR Purification Kit (Qiagen). Sequence analysis was carried out

at the Synthesis and Sequencing Facility at Johns Hopkins University using a 3730xl DNA Analyzer (Applied Biosystems). PCR primer sequences for *PCDH17* and *SOX17* genes are summarized in Supplementary Table S2.

MSP

MSP was conducted as previously described using 10 ng of input DNA for each MSP reaction (24). Primer sequences for the 11 genes identified as differentially methylated are provided in Supplementary Table S2.

5-Aza-2'-deoxycytidine treatment

Cell lines were treated with 1 $\mu\text{mol/L}$ of 5-aza-2'-deoxycytidine (5-aza-dC; Sigma-Aldrich) for 4 days as we described previously (17).

RNA isolation and real-time PCR

Total RNA was extracted using the mirVana miRNA Isolation Kit (Ambion) and reverse transcribed using Superscript III Reverse Transcriptase and oligodT (Invitrogen) for quantitative reverse transcriptase-PCR (RT-PCR) following the manufacturer's protocol. The cDNAs for *SOX17* and *EBF3* were quantified with SYBR Green PCR Master Mix (Applied Biosystems). PCR was carried out with a StepOnePlus Real time PCR system (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a reference for SYBR Green. Relative expression was determined with the $\Delta\Delta C_t$ method. The primer sequences and PCR conditions are summarized in Supplementary Table S2.

Immunohistochemistry

Immunohistochemistry was conducted as previously described on 88 IPMNs, including 75 IPMNs on tissue microarrays and 13 IPMNs on conventional slides, and 111 pancreatic ductal adenocarcinomas on tissue microarrays. The antigen retrieval step was carried out in a steam pressure cooker containing preheated high pH antigen retrieval buffer (DakoCytomation) at 95°C for 20 minutes. To minimize nonspecific antibody binding, sections were incubated with protein blocker (DakoCytomation) for 10 minutes and stained using the LSAB Detection Method (DAKO). Primary anti-Sox17 (GT15094, anti-goat antibody, Neuromics Antibodies, 1:400 dilution) monoclonal antibodies was applied manually to the sections and incubated for 30 minutes at room temperature. The remaining steps were conducted using an automated immunostainer (DakoCytomation). Immunolabeled sections were lightly counterstained with hematoxylin, dehydrated in ethanol, and cleared in xylene. Immunohistochemical labeling of Sox17 protein was scored using a previously described histologic score quantifying both the area and intensity of labeling (32). Labeling intensity was designated as 0 to 2 for absent, weak, and strong, and the area of labeling was designated as 0 to 4 for <5%, 5%–25%, 26%–50%, 51%–75%, and >76%, respectively (32). Sox17 expression was classified as reduced when less than 50% of tumor cells were labeled.

Statistical analysis

The mean number of methylated genes was in subtypes of IPMN were compared by Student *t* test and Mann–Whitney *U* test. The proportion of genes methylated in each group was compared by ANOVA and *post hoc* Duncan tests. Associations between categorical variables were examined with Pearson χ^2 and Fisher exact tests. Linear regression analysis was conducted to examine the relationship between patients' age and the number of methylated genes. Statistical analyses were conducted with SPSS version 17 (IBM SPSS). A *P* value < 0.05 was considered statistically significant.

Results

Characteristics of cases

The 6 patients whose IPMNs were analyzed by MCAM included 3 males and 3 females, their mean age was 65.8 \pm 11.9 years (range, 48–79 years). One patient had an IPMN with low-grade dysplasia (6T), 3 had IPMNs with intermediate-grade dysplasia (2T, 55T, and 60T), and 2 had IPMNs with high-grade dysplasia (4T and 11T). The pooled normal pancreatic duct samples were obtained from 3 of these patients (2T, 4T, and 6T).

Identification of differentially methylated loci between IPMN and normal pancreatic ducts

Six MCA experiments were carried out using the Agilent 244K CpG island microarrays with each MCA experiment comparing an IPMN with pooled laser-captured microdissected normal pancreatic duct samples. A ≥ 4 -fold differential methylation (NLR >2 or <–2) in the IPMNs relative to the normal pancreas was used to identify differentially methylated probes. This cutoff was validated using bisulfite sequencing (30). On the basis of this criterion, the number of probes and genes differentially methylated in each paired IPMN/normal pancreatic duct sample was 1,338 probes/745 genes (6T, low-grade dysplasia); 893 probes/515 genes (2T, intermediate-grade dysplasia); 1,204 probes/726 genes (55T, intermediate-grade); 1,158 probes/688 genes (60T, intermediate-grade dysplasia); 1,295 probes/710 genes (4T, high-grade dysplasia); and 8,449 probes/5,091 genes (11T, high-grade dysplasia). Overall, there were 10,323 uniquely hypermethylated probes in at least 1 of the 6 IPMN/normal pancreatic duct pairs representing 2,195 loci and 2,244 genes (Supplementary Table S3).

To identify more commonly hypermethylated genes, we determined the probes and genes hypermethylated in 2 or more of the 6 IPMNs evaluated by MCAM analysis. The resulting list included 2,406 hypermethylated probes representing 692 loci and 708 genes (Supplementary Table S4).

Understanding the molecular events associated with high-grade IPMN neoplasia is particularly important not only because of their potential biologic importance but also because IPMNs with high-grade dysplasia (high-grade IPMNs) warrant surgical resection and markers of high-grade IPMNs could have diagnostic use. We therefore identified probes differentially methylated in the 2 high-grade

IPMNs compared with normal pancreatic duct samples. This comparison yielded 840 probes, corresponding to 245 genes (Supplementary Table S5). Of these 245 hypermethylated genes, 53 genes were only hypermethylated in both of the high-grade IPMNs (Supplementary Table S6).

Many on this list of 245 hypermethylated genes have been identified as aberrantly methylated in ductal adenocarcinomas of the pancreas, including *ADCYAP1*, *ALK*, *CCNA1*, *EYA4*, *GALR1*, *LHX1*, *LHX2*, *LIN28*, *MYOD1*, *MDFI*, *NPY*, *NRN1*, *NRXN1*, *PAX1*, *PENK*, *PITX2*, *TFPI2*, *SALL3*, *SLIT2*, *SOX17*, *TLX3*, and *ZNF415* (17, 18, 20, 30, 33). We also confirmed our previous findings of aberrant methylation of the genes *TFPI2*, *SARP2/SFRP1*, *PENK*, and *CLDN5* in a subset of IPMNs (23, 24). The genes, *DLX1*, *EVX2*, and *TBX18*, have been reported to be abnormally hypermethylated in other cancers (Supplementary Table S7).

Some important genes were methylated in only one of the IPMNs including *CDKN2A/p16* (Supplementary Table S2). Several genes methylated in less than 10% of pancreatic cancers such as *CDH1/e-cadherin* and *hMLH1* (22, 23) were not identified as methylated in any of the IPMNs.

Differentially hypermethylated genes in IPMNs versus pancreatic cancers

We compared the number of differentially methylated genes in IPMNs with those of pancreatic cancers obtained using the same MCAM strategy used to profile IPMNs (34). The median number of probes methylated in the IPMNs was 1,249.5 and for pancreatic cancer it was 7,713 ($P = 0.018$, Mann-Whitney *U* test). The median number of hypermethylated genes in IPMNs relative to normal pancreatic duct ($506 \pm 1,804.0$ genes) was significantly lower than in nine pancreatic cancers relative to normal pancreatic duct ($2,285.7 \pm 608.2$ genes; $P = 0.04$).

Validation of hypermethylated genes by MCAM analysis

To confirm the accuracy of our MCAM data, we used MSP to evaluate the methylation status of 13 genes in an independent set of 61 IPMNs and 43 normal pancreas samples. Genes that were selected had multiple probes identified as differentially methylated by MCAM. These genes were analyzed in an independent set of IPMNs and normal pancreas samples. This analysis was limited to 13 genes because the amount of available DNA from our tumor samples available for these assays after bisulfite modification was limited. Indeed, 3 of the genes were tested in a smaller set of IPMNs and normal pancreas samples (*BNIP3*, *PTCHD2*, and *LIN28*) because of limited sample availability. Most of these genes, including *BNIP3*, *PTCHD2*, *LIN28*, *NXP1*, *SOX17*, *EBF3*, *PAX6*, *FOXF2*, *PCDH17*, and *SALL3*, were identified as methylated by MCAM analysis in the high-grade IPMNs. Representative images of results of MSP are depicted in Supplementary Fig. S1. The demographic and clinicopathologic information of the 65 patients whose IPMNs were studied is summarized in Table 1 and Supplementary Table S1. Two of 6 IPMN samples used for MCAM were included in the validation, one an IPMN with low-grade dysplasia and the other an IPMN with intermediate dysplasia, and the

results of MSP and MCAM were 100% concordant in these two samples.

Overall, the genes tested for methylation by MSP analysis confirmed the results of the MCAM array analysis, showing that the majority of genes tested were commonly methylated in the IPMNs, compared with much lower prevalence of methylation in normal pancreas (<10% of samples for most genes evaluated). Two of the 13 genes tested (*IRX2* and *HOXA5*) were not identified as differentially methylated in IPMNs relative to normal pancreatic duct samples by MSP (methylated DNA was as prevalent in normal as in IPMN samples).

By MSP analysis, significantly more genes were methylated in IPMNs than in normal pancreas and higher grade IPMNs had more methylated genes than lower-grade IPMNs. Thus, $48.4\% \pm 21.9\%$ of genes were methylated in IPMNs with low-grade dysplasia, $52.2\% \pm 24.2\%$ in IPMNs with intermediate-grade dysplasia, $73.9\% \pm 20.9\%$ in IPMNs with high-grade dysplasia, and $85.1\% \pm 18.5\%$ in IPMNs with an associated invasive adenocarcinoma ($P < 0.0001$, ANOVA; Supplementary Fig. S2). More genes were methylated in IPMNs with high-grade dysplasia or with associated invasive adenocarcinoma than IPMNs with low-grade dysplasia or with intermediate-grade dysplasia ($P < 0.05$, *post hoc* Duncan test). And more genes were methylated in IPMNs with low-grade dysplasia or IPMNs with intermediate-grade dysplasia than in normal pancreata ($P < 0.05$, *post hoc* Duncan test). These results are summarized in Table 2 and Supplementary Fig. S2. These results are consistent with our previous investigations of IPMN methylation investigating candidate genes that had been identified as aberrantly methylated in pancreatic ductal adenocarcinomas (23, 24). In this previous study, we also found an overall trend for a higher prevalence of aberrant methylation in higher grade IPMNs, but this was limited to some genes (e.g., *TFPI-2*, *TSLC1*, *SARP2*, *UCHL1*, *CLDN5*), whereas for other genes, aberrant methylation is common even in low-grade IPMNs (*SPARC* and *RELN*).

Because IPMNs can be subclassified by their anatomic localization and their histologic subtype, we compared DNA methylation profiles within these subgroups. The percentage of genes methylated in main-duct IPMNs ($71.3\% \pm 23.8\%$) was significantly higher than those in branch-duct type ($44.4\% \pm 20.0\%$, $P < 0.0001$). Main-duct IPMNs are more likely to be associated with high-grade lesions and invasive adenocarcinomas, and once histologic grade is taken into account, the relationship between the number and pattern of methylated genes with IPMN location was no longer significant. IPMNs also can be subclassified by their histologic phenotypes into pancreatobiliary, intestinal, and gastric subtypes. We found that the percentage of genes methylated in pancreatobiliary type IPMNs (72.8 ± 22.6) was significantly higher than gastric-type IPMN (51.2 ± 22.5 , $P = 0.001$, Student *t* test) but not after adjusting for grade of IPMN. Similarly, there was a borderline difference in the percentage of genes methylated in gastric- versus intestinal-type IPMNs (64.9 ± 26.5 ; $P = 0.08$)

Table 2. Summary of methylation profiles of each grade of IPMNs, and IPMNs with associated invasive adenocarcinomas arising in IPMNs, and peritumoral normal pancreatic tissues determined by MSP

| Patients no. | Age | Sex | Ethnicity | IPMNs ductal subtype | Histologic subtype | SOX17 | | PAX6 | | SALL1 | | SALL3 | | FOXF2 | | NXP1 | | EBF3 | | PCDH17 | | LIN28A | | PTCHD2 | | BNIP3 | | No. of methylated genes | % of methylated genes |
|-----------------------------------|------|-----|-----------|----------------------|--------------------|-------|------|------|-------|-------|-------|-------|------|-------|------|------|------|------|------|--------|-----|--------|-----|--------|-----|-------|---|-------------------------|-----------------------|
| | | | | | | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | | |
| IPMNs with low-grade dysplasia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 01L | 82 | M | C | Main | Gastric | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | 3/7 | 43 |
| 12L | 76 | F | C | Main | Gastric | M | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 6/8 | 75 |
| 17L | 77 | F | C | Main | Gastric | M | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 4/4 | 100 |
| 32L | 69 | M | C | Main | Gastric | M | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 5/8 | 63 |
| 34L | 47 | M | C | Branch | Gastric | U | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 4/11 | 36 |
| 37L | 72 | F | C | Branch | Gastric | U | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 5/11 | 45 |
| 38L | 66 | F | C | Main | Gastric | U | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 5/8 | 63 |
| 39L | 63 | M | C | Unknown | Gastric | U | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 4/11 | 36 |
| 40L | 57 | M | C | Branch | Gastric | U | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 5/11 | 45 |
| 43L | 72 | F | C | Branch | Gastric | U | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 7/11 | 64 |
| 46L | 72 | F | C | Branch | Gastric | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 2/8 | 25 |
| 47L | 56 | F | C | Branch | Gastric | U | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 3/11 | 27 |
| 57L | 53 | F | C | Branch | Gastric | M | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 3/11 | 27 |
| 63L | 59 | M | C | Branch | Gastric | U | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 3/11 | 27 |
| | 4/14 | | | | | 29% | 5/14 | 33% | 12/14 | 86% | 13/14 | 93% | 6/12 | 50% | 2/13 | 15% | 3/13 | 23% | 6/11 | 55% | 6/8 | 75% | 0/8 | 0% | 0/8 | 0% | | 48 | |
| IPMNs with intermediate dysplasia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 141 | 69 | M | C | Main | Pancreatobiliary | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | 5/7 | 71 |
| 181 | 60 | F | AA | Main | Pancreatobiliary | M | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 4/8 | 50 |
| 221 | 74 | F | C | Main | Pancreatobiliary | M | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 7/10 | 70 |
| 271 | 73 | M | C | Main | Pancreatobiliary | M | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | M | 10/10 | 100 |
| 331 | 79 | M | C | Main | Intestinal | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 1/6 | 17 |
| 361 | 82 | M | C | Unknown | Gastric | M | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 4/6 | 67 |
| 411 | 55 | F | C | Branch | Gastric | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | U | 5/8 | 63 |
| 441 | 78 | F | C | Unknown | Pancreatobiliary | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | U | 6/10 | 60 |
| 491 | 81 | F | C | Branch | Gastric | M | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 6/11 | 55 |
| 501 | 72 | F | C | Branch | Gastric | M | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 7/10 | 70 |
| 511 | 61 | F | C | Branch | Intestinal | M | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | U | 7/8 | 88 |
| 551 | 84 | F | C | Main | Pancreatobiliary | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | U | 4/10 | 40 |
| 581 | 61 | M | C | Branch | Intestinal | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | U | 4/10 | 40 |
| 591 | 80 | M | C | Main | Pancreatobiliary | FA | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | M | U | U | 4/9 | 44 |
| 601 | 72 | F | H | Branch | Intestinal | U | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 3/11 | 27 |
| 621 | 56 | M | C | Branch | Gastric | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 1/11 | 9 |

(Continued on the following page)

Table 2. Summary of methylation profiles of each grade of IPMNs, and IPMNs with associated invasive adenocarcinomas arising in IPMNs, and peritumoral normal pancreatic tissues determined by MSP (Cont'd)

| Patients no. | Age | Sex | Ethnicity | IPMN ductal subtype | Histologic subtype | SOX17 | PAX6 | SALL1 | SALL3 | FOXF2 | NXP1 | EBF3 | PCDH17 | LIN28A | PTCHD2 | BNIP3 | No. of methylated genes | % of methylated genes |
|--------------------------------|-----|-----|-----------|---------------------|--------------------|-------|------|-------|-------|-------|-------|------|--------|--------|--------|-------|-------------------------|-----------------------|
| | | | | | | | | | | | | | | | | | | |
| 64I | 73 | M | C | Branch | Gastric | M | U | M | FA | U | U | M | M | NT | NT | NT | 4/7 | 57 |
| 65I | 56 | M | C | Main | Pancreatobiliary | U | U | FA | M | M | U | U | U | M | U | U | 3/10 | 30 |
| 67I | 87 | F | C | Main | Intestinal | U | U | M | U | FA | M | U | M | M | M | M | 6/10 | 60 |
| 69I | 72 | F | H | Main | Intestinal | NT | NT | NT | NT | NT | NT | NT | NT | U | U | U | 2/3 | 67 |
| 74I | 66 | M | C | Main | Intestinal | NT | NT | NT | NT | NT | NT | NT | NT | M | U | U | 1/3 | 33 |
| 73I | 66 | M | C | Main | Gastric | NT | NT | NT | NT | NT | NT | NT | NT | M | U | U | 1/3 | 33 |
| | | | | | | 8/18 | 9/18 | 13/18 | 12/18 | 10/17 | 10/19 | 7/16 | 8/16 | 12/15 | 3/11 | 3/15 | | 52 |
| | | | | | | 44% | 50% | 72% | 67% | 59% | 53% | 44% | 50% | 80% | 27% | 20% | | |
| IPMN with high-grade dysplasia | | | | | | | | | | | | | | | | | | |
| 05H | 81 | M | C | Main | Pancreatobiliary | M | U | M | M | M | M | U | U | NT | NT | NT | 5/8 | 63 |
| 06H | 35 | M | C | Main | Intestinal | FA | U | U | M | M | U | NT | NT | NT | NT | NT | 2/5 | 40 |
| 07H | 68 | F | C | Main | Pancreatobiliary | M | M | U | M | M | M | M | M | NT | NT | NT | 7/8 | 88 |
| 09H | 59 | M | C | Unknown | Pancreatobiliary | NT | M | U | M | M | U | U | U | NT | NT | NT | 3/6 | 50 |
| 13H | 57 | M | C | Unknown | Pancreatobiliary | U | M | M | M | M | M | U | U | NT | NT | NT | 5/8 | 63 |
| 15H | 68 | M | C | Main | Pancreatobiliary | M | M | M | M | NT | NT | NT | NT | NT | NT | NT | 4/4 | 100 |
| 19H | 74 | F | C | Main | Gastric | M | M | M | M | M | M | NT | NT | NT | NT | NT | 6/6 | 100 |
| 20H | 65 | M | C | Main | Pancreatobiliary | M | M | M | M | M | M | M | M | M | U | M | 8/8 | 100 |
| 23H | 80 | M | C | Main | Intestinal | M | M | M | M | NT | NT | NT | NT | NT | NT | NT | 4/4 | 100 |
| 25H | 66 | F | C | Main | Pancreatobiliary | FA | M | M | M | M | M | U | U | M | M | M | 5/7 | 71 |
| 26H | 56 | M | C | Main | Pancreatobiliary | M | U | M | M | M | M | U | M | U | U | M | 7/8 | 88 |
| 28H | 76 | M | C | Main | Pancreatobiliary | M | M | M | M | U | U | U | M | M | U | U | 5/8 | 63 |
| 31H | 80 | F | C | Main | Intestinal | M | U | M | M | M | M | U | M | M | M | M | 7/8 | 88 |
| 42H | 76 | M | C | Main | Intestinal | U | M | M | M | M | M | M | M | NT | NT | NT | 7/8 | 88 |
| 45H | 76 | M | O | Main | Pancreatobiliary | M | U | M | M | M | M | NT | NT | NT | NT | NT | 5/7 | 71 |
| 48H | 63 | M | C | Main | Intestinal | M | M | M | M | M | M | U | M | M | M | M | 6/8 | 75 |
| 52H | 74 | F | C | Main | Pancreatobiliary | M | M | M | M | M | M | M | M | M | M | U | 8/8 | 100 |
| 53H | 53 | M | C | Main | Intestinal | M | M | M | M | FA | M | U | M | M | M | M | 6/7 | 86 |
| 54H | 50 | M | O | Main | Pancreatobiliary | M | U | M | M | U | M | M | U | M | U | M | 4/8 | 50 |
| 56H | 66 | M | C | Main | Intestinal | FA | M | M | M | FA | M | U | U | NT | NT | NT | 4/6 | 67 |
| 61H | 68 | M | C | Branch | Gastric | U | U | M | M | M | U | U | U | M | U | U | 4/8 | 50 |
| 66H | 58 | M | C | Main | Pancreatobiliary | FA | M | M | M | U | U | M | U | M | U | U | 3/6 | 50 |
| 71H | 35 | M | C | Main | Intestinal | NT | NT | NT | NT | NT | NT | NT | NT | M | M | U | 2/3 | 67 |
| 72H | 81 | M | C | Main | Pancreatobiliary | NT | NT | NT | NT | NT | NT | NT | NT | M | U | U | 1/3 | 33 |
| 75H | 60 | M | C | Main | Pancreatobiliary | NT | NT | NT | NT | NT | NT | NT | NT | M | M | M | 3/3 | 100 |

(Continued on the following page)

Table 2. Summary of methylation profiles of each grade of IPMNs, and IPMNs with associated invasive adenocarcinomas arising in IPMNs, and peritumoral normal pancreatic tissues determined by MSP (Cont'd)

| Patients no. | Age | Sex | Ethnicity | IPMN ductal subtype | Histologic subtype | Methylation profiles (%) | | | | | | | | | | | No. of methylated genes | % of methylated genes | | | | | | | | |
|---|-----|-----|-----------|---------------------|--------------------|--------------------------|------|-------|-------|-------|------|------|--------|--------|--------|-------|-------------------------|-----------------------|------|------|------|------|------|-----|------|-----|
| | | | | | | SOX17 | PAX6 | SALL1 | SALL3 | FOXF2 | NXP1 | EBF3 | PCDH17 | LIN28A | PTCHD2 | BNIP3 | | | | | | | | | | |
| IPMN with associated invasive adenocarcinoma | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 03CA | 79 | F | C | Main | Pancreatobiliary | NT | NT | NT | M | M | M | M | U | U | U | M | NT | NT | NT | NT | NT | NT | NT | 2/2 | 100 | |
| 04CA | 77 | F | C | Main | Intestinal | NT | M | M | M | M | M | M | M | M | M | NT | NT | NT | NT | NT | NT | NT | NT | NT | 6/6 | 100 |
| 07CA | 68 | F | C | Main | Pancreatobiliary | U | U | M | M | M | M | M | U | U | U | M | M | NT | NT | NT | NT | NT | NT | NT | 5/8 | 63 |
| 12CA | 76 | F | C | Main | Gastric | FA | FA | M | M | U | U | U | U | U | U | NT | NT | NT | NT | NT | NT | NT | NT | NT | 2/4 | 50 |
| 18CA | 60 | F | AA | Main | Pancreatobiliary | M | M | M | M | U | U | U | U | U | U | M | M | NT | NT | NT | NT | NT | NT | NT | 5/7 | 71 |
| 22CA | 74 | F | C | Main | Pancreatobiliary | U | M | M | M | NT | NT | NT | NT | NT | NT | M | M | M | NT | NT | NT | NT | NT | NT | 4/5 | 80 |
| 24CA | 83 | F | AA | Main | Pancreatobiliary | M | M | M | M | M | M | M | M | M | M | M | M | M | M | NT | NT | NT | NT | NT | 8/8 | 100 |
| 25CA | 66 | F | C | Main | Pancreatobiliary | M | U | M | FA | FA | FA | FA | FA | FA | FA | M | M | M | NT | NT | NT | NT | NT | NT | 7/8 | 88 |
| 27CA | 73 | M | C | Main | Pancreatobiliary | M | M | M | M | M | M | M | M | M | M | M | M | M | M | NT | NT | NT | NT | NT | 8/8 | 100 |
| 28CA | 76 | M | C | Main | Pancreatobiliary | M | M | M | M | M | M | M | M | M | M | M | M | M | M | NT | NT | NT | NT | NT | 8/8 | 100 |
| | | | | | | 5/8 | 6/8 | 9/10 | 9/10 | 6/9 | 7/9 | 8/8 | 7/7 | 10/18 | 13/14 | 7/14 | 8/14 | 8/14 | 8/14 | 8/14 | 8/14 | 8/14 | 8/14 | 57% | 74 | |
| | | | | | | 63% | 75% | 90% | 90% | 67% | 78% | 100% | 100% | 56% | 93% | 50% | 57% | 57% | 57% | 57% | 57% | 57% | 57% | 57% | 57% | |
| Normal from endocrine neoplasm | | | | | | | | | | | | | | | | | | | | | | | | | | |
| NE01 | 46 | M | C | NA | NA | U | U | U | U | U | U | U | U | U | U | M | U | U | U | U | U | U | U | U | 1/8 | 13 |
| NE02 | 63 | F | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 0/8 | 0 |
| NE03 | 42 | F | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 0/8 | 0 |
| NE04 | 39 | F | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 0/5 | 0 |
| NE08 | 56 | F | C | NA | NA | U | U | U | U | U | U | U | U | U | U | M | U | U | U | U | U | U | U | U | 2/8 | 25 |
| NE09 | 78 | M | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 0/8 | 0 |
| NE10 | 41 | F | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 0/8 | 0 |
| NE11 | 57 | M | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 0/8 | 0 |
| | | | | | | 0/8 | 0/8 | 0/8 | 1/8 | 0/7 | 1/7 | 1/8 | 100% | 13% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 5 | |
| | | | | | | 0% | 0% | 0% | 13% | 0% | 0% | 14% | 13% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Normal from IPMN or cancer | | | | | | | | | | | | | | | | | | | | | | | | | | |
| NLPDA01 | 62 | M | AA | NA | NA | U | U | U | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 1/8 | 13 |
| NLPDA02 | 61 | M | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 1/11 | 9 |
| NLPDA03 | 78 | F | C | NA | NA | U | U | U | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 2/10 | 20 |
| NLPDA04 | 59 | F | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 1/11 | 9 |
| NLPDA05 | 56 | F | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 0/11 | 0 |
| NLPDA06 | 78 | M | C | NA | NA | U | U | U | M | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 2/11 | 18 |
| NLPDA07 | 61 | F | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | U | 2/6 | 33 |

(Continued on the following page)

Table 2. Summary of methylation profiles of each grade of IPMNs, and IPMNs with associated invasive adenocarcinomas arising in IPMNs, and peritumoral normal pancreatic tissues determined by MSP (Cont'd)

| Patients no. | Age | Sex | Ethnicity | IPMN ductal subtype | Histologic subtype | Methylation status (M = methylated, U = unmethylated, NA = not applicable) | | | | | | | | | | No. of methylated genes | % of methylated genes | | |
|--------------|-----|-----|-----------|---------------------|--------------------|--|------|-------|-------|-------|-------|------|--------|--------|--------|-------------------------|-----------------------|-------|----|
| | | | | | | SOX17 | PAX6 | SALL1 | SALL3 | FOXF2 | NXPH1 | EBF3 | PCDH17 | LIN28A | PTCHD2 | | | BNIP3 | |
| NLPDA08 | 76 | M | C | NA | NA | U | U | M | U | U | U | U | U | U | M | U | U | 2/11 | 18 |
| NLPDA09 | 51 | M | C | NA | NA | U | M | M | U | U | U | U | U | U | U | U | U | 5/8 | 63 |
| NLPDA10 | 70 | M | C | NA | NA | U | M | U | U | U | U | U | U | U | U | U | U | 1/8 | 13 |
| NLPDA11 | 78 | F | C | NA | NA | U | U | U | U | M | U | U | U | U | U | U | U | 1/8 | 13 |
| NLPDA14 | 59 | M | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | 0/8 | 0 |
| NLPDA15 | 56 | M | O | NA | NA | U | U | M | U | U | U | U | U | U | U | U | U | 1/5 | 20 |
| NLPDA16 | 72 | M | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | 0/6 | 0 |
| NLPDA17 | 72 | M | C | NA | NA | U | M | U | U | U | U | U | U | U | U | U | U | 3/11 | 27 |
| NLPDA18 | 76 | M | C | NA | NA | U | M | U | U | U | U | U | U | U | U | U | U | 3/8 | 38 |
| NLPDA21 | 60 | F | C | NA | NA | U | U | M | U | U | U | U | U | U | U | U | U | 2/11 | 18 |
| NLPDA22 | 31 | M | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | 0/11 | 0 |
| NLPDA23 | 53 | M | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | 0/11 | 0 |
| NLPDA24 | 58 | M | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | 1/11 | 9 |
| NLPDA25 | 59 | F | C | NA | NA | U | M | U | U | U | U | U | U | U | U | U | U | 3/11 | 27 |
| NLPDA26 | 51 | M | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | 0/11 | 0 |
| NLPDA27 | 60 | F | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | 0/11 | 0 |
| NLPDA28 | 54 | M | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | 0/11 | 0 |
| NLPDA29 | 52 | M | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | 0/8 | 0 |
| NLPDA31 | 66 | M | C | NA | NA | U | M | U | U | U | U | U | U | U | U | U | U | 3/11 | 27 |
| NLPDA32 | 62 | M | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | 0/11 | 0 |
| NLPDA33 | 84 | F | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | 0/8 | 0 |
| NLPDA34 | 81 | M | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | 0/8 | 0 |
| NLPDA35 | 66 | M | C | NA | NA | U | U | U | U | U | M | U | U | U | U | U | U | 1/8 | 13 |
| NLPDA36 | 64 | F | C | NA | NA | U | U | U | U | U | U | U | U | U | U | U | U | 0/8 | 0 |
| NLPDA37 | 70 | F | C | NA | NA | U | U | U | M | U | U | U | U | U | U | U | U | 2/8 | 25 |
| NLPDA38 | 78 | M | C | NA | NA | U | U | U | M | U | U | U | U | U | U | U | U | 1/8 | 13 |
| NLPDA39 | 74 | F | C | NA | NA | U | U | U | M | U | U | U | U | U | U | U | U | 1/8 | 13 |
| NLPDA40 | 88 | F | C | NA | NA | U | U | U | M | U | U | U | U | U | U | U | U | 2/11 | 18 |
| | | | | | | 3/35 | 5/35 | 5/34 | 11/35 | 7/34 | 2/33 | 0/33 | 2/32 | 5/18 | 1/18 | 0/18 | | 13 | |
| | | | | | | 9% | 14% | 15% | 31% | 21% | 6% | 0% | 6% | 28% | 6% | 0% | | | |

NOTE: **M** box indicates completely methylated. **M** box indicates partially methylated. Abbreviations: FA, failed to amplify; M, methylated; NA, not applicable; NT, not tested; U, unmethylated.

but this difference was also not significant after adjusting for neoplastic grade.

The number of genes methylated in normal pancreatic tissues from patients with ductal neoplasms was marginally but not significantly higher than in those from patients with well-differentiated pancreatic endocrine neoplasms ($13.0\% \pm 13.9\%$ vs. $4.7\% \pm 9.3\%$, $P = 0.08$, Mann-Whitney U test) which could be related to patient age as the mean age of patients with ductal neoplasia (65 ± 12 years) was significantly higher than in those with well-differentiated pancreatic endocrine neoplasms (53 ± 13 years, $P = 0.02$, Mann-Whitney U test). Among patients with IPMNs, we found a significant correlation between patient age and the number of methylated genes in their IPMN ($P < 0.001$, $R = 0.34$, linear regression analysis). There was no evidence that this was related to IPMN grade as there was no significant difference in patient age by IPMN grade in our study population. These results are similar to our previous analysis of methylation in pancreatic samples (24) where with a different panel of genes we observed a small but significantly higher number of methylated genes in the normal pancreata of patients with ductal neoplasms compared with patients with neuroendocrine tumors (24).

We next compared the progression of individual gene methylation by neoplastic grade. Aberrant hypermethylation of *BNIP3* was more common in IPMNs with high-grade dysplasia (57%, 8 of 14 cases) than in those with intermediate-grade (20%, 3 of 15 cases, $P = 0.06$) or low-grade dysplasia (0%, 0 of 8 cases, $P = 0.02$) and more common than in normal pancreas samples (0%, 0 of 18 cases, $P < 0.001$). Similarly, *PTCHD2* methylation was also significantly more common in IPMNs with high-grade dysplasia (50%, 7 of 14 cases) than in those with low-grade dysplasia (0%, 0 of 8 cases, $P = 0.02$) or normal pancreas (6%, 1 of 18 cases, $P = 0.001$). *PTCHD2* methylation is also detected in a smaller percentage of IPMNs with intermediate-grade dysplasia (27%, 3 of 11 cases). There was also evidence of increasing methylation of *EBF3* ($P = 0.01$; χ^2 test), *SOX17* ($P = 0.01$), and *NXP1* ($P = 0.001$) by neoplastic grade, but not for any of the other genes analyzed, *PAX6* ($P = 0.16$), *SALL1* ($P = 0.68$), *FOXF2* ($P = 0.13$), *SALL3* ($P = 0.14$), or *PCDH17* ($P = 0.13$). The presence of methylation in at least one of the two markers most specifically associated with high-grade dysplasia (*BNIP3* and *PTCHD2*) had a sensitivity of 71% (10 of 14).

SOX17 expression analysis

To evaluate the expression of one of the aberrantly methylated genes in IPMNs, we selected *SOX17* a gene with an available antibody to its protein product. (There were no commercially antibodies available that had been shown to work for immunohistochemistry to the protein products of other genes we analyzed by MSP.) We next examined the expression of the protein product of one of the genes commonly methylated in IPMNs by immunohistochemistry. Among 88 resected primary IPMNs (see Fig. 2 for representative images), Sox17 protein expression was significantly lower in IPMNs than in associated normal pan-

creatic duct (histologic score 3.0 ± 2.2 vs. 7.8 ± 0.7 , Student t test, $P < 0.001$). Sox17 expression was absent in 27% (4 of 15) of low-grade IPMNs, 21% (6 of 29) of intermediate-grade IPMNs, and 20% (9 of 44) of high-grade IPMNs. Reduced expression of Sox17 was observed in 60% (9 of 15) of low-grade IPMNs, 69% (20 of 29) of intermediate-grade IPMNs, and 75% (33 of 44) of high-grade IPMNs. Loss of Sox17 expression in IPMNs was not associated with clinicopathologic factors such as histologic subtype, grade, and tumor location. We also observed complete loss of Sox17 in a similar proportion of pancreatic ductal adenocarcinomas (29%, 32 of 111).

We also found evidence for epigenetic regulation of Sox17 expression in pancreatic cancer cells. *SOX17* RNA was upregulated in several pancreatic cancer cell lines, including A32-1, Capan1, FamPanc, and Panc2.5, after 5-aza-dC treatment (Supplementary Fig. S3). We also conducted bisulfite sequencing of *SOX17* in pancreatic cancer cell lines and found methylation of most of the CpGs in the 5' region of *SOX17* in 6 pancreatic cancer cell lines tested, and it was predominantly unmethylated in 6 normal pancreatic samples, and the nonneoplastic cell line, HPDE (Supplementary Fig. S4). Similarly, 5' CpGs of *PCDH17* were predominantly methylated in 11 pancreatic cancer samples and predominantly unmethylated in 5 of 8 normal pancreatic tissue samples (Supplementary Fig. S5).

Discussion

In this study, we find that the pancreatic precursor neoplasms known as IPMNs are characterized by widespread aberrant hypermethylation affecting several hundred CpG islands. Extensive aberrant hypermethylation has been shown in pancreatic and other invasive cancers, but the timing of such aberrant methylation during tumor development has not been well established. In our study, we find that even low-grade IPMNs harbor aberrant methylation of hundreds of CpG islands, with evidence of increased levels of methylation with increasing neoplastic grade. Consistent with this trend is the finding that significantly more genes are methylated in pancreatic ductal adenocarcinomas than in IPMNs.

Among the genes tested, both *BNIP3* and *PTCHD2* had promising performance characteristics as diagnostic markers of IPMNs with high-grade dysplasia. Aberrant methylation of *BNIP3* has been described in pancreatic ductal adenocarcinomas but not in IPMNs (35). *PTCHD2/DISP3* is a transmembrane protein and shares a PTCH/DISP homologous domain and aberrant methylation of *PTCHD2/DISP3* has not been described in any solid cancer.

Our MCAM analysis identified other genes that were selectively methylated in high-grade IPMNs including the gene *TFPI-2*, which we have previously described as much more commonly methylated in high-grade IPMNs and infiltrating adenocarcinomas than in low or intermediate grade of IPMNs (24). Because most IPMNs are detected incidentally when they are small neoplasms of low malignant potential, they are managed by surveillance and only




Figure 2. Immunohistochemical analysis of Sox17 protein expression of IPMNs (A) Sox17 labeling in normal pancreatic ductal epithelial cells and acinar cells (20 \times). Lack of tumoral Sox17 expression in (B) an IPMN with low-grade dysplasia (10 \times), (C and D) an IPMN with intermediate-grade dysplasia (20 \times), and (E) an IPMN with high-grade dysplasia (20 \times). F, an IPMN with high-grade dysplasia expressing Sox17. Stromal fibroblasts expressed Sox17.

undergo resection when there is a concern for high-grade neoplasia or malignancy. Because imaging tests cannot differentiate low-grade from high-grade neoplastic lesions, markers that can reliably identify the grade of neoplasia in IPMNs could help determine the optimal timing of resection for patients undergoing surveillance (36). Genes with methylation profiles highly specific for high-grade dysplasia in IPMNs could be useful as markers for detection in fine-needle aspirates of IPMN samples (3, 36–38).

Of the 2,244 genes identified as aberrantly methylated in any IPMN, many have been identified as aberrantly methylated in pancreatic cancers, including genes bound by polycomb and those involving pathways and gene families commonly targeted in pancreatic ductal adenocarcinomas. For example, of the 331 aberrantly methylated genes involved in transcription regulation, many were members of the homeobox superfamily. Indeed, 41 of the 245 aberrantly methylated genes in high-grade IPMNs were homeobox genes. Homeobox genes encode transcription factors and play a key role in development by activating or repressing downstream target genes involved in many cellular processes, including adhesion, apoptosis, body patterning, differentiation, migration, proliferation, polarity, and proliferation and are commonly observed in cancers (39).

Several members of the Wnt signaling pathway were also found to be hypermethylated in IPMNs by MCAM analysis

including multiple genes previously shown to be epigenetically silenced in both invasive pancreatic and other types of cancer such as *FZD10*, *SFRP1*, *APC2*, *SOX11*, and *SOX17*. *SOX17* is expressed in the developing pancreas and has an important role in endoderm development (40). Sox17 represses the Wnt/ β -catenin signaling pathway (41) and its silencing has been reported in colorectal and stomach cancers (41, 42). We and others have previously described aberrant hypermethylation of *SOX17* in pancreatic cancers (30, 33). In this study, we find that aberrant hypermethylation of *SOX17* and silencing of its protein product is evident early during pancreatic neoplastic development and the prevalence of methylation increases with IPMN grade, and this was associated with silencing of *SOX17* expression in about one fourth of IPMNs and pancreatic ductal adenocarcinomas.

Another gene we found to be commonly methylated in IPMNs was the putative tumor suppressor gene *EBF3/COE3* which encodes a transcription factor involved in regulating differentiation and neurogenesis (43). Although aberrant methylation of *EBF3* has not been reported in pancreatic neoplasms previously, such methylation has been reported in several cancers, including glioblastoma and head and neck squamous cell carcinomas (43, 44). Furthermore, *EBF3* mutation has been described (45). Methylation of *EBF3* by MSP was detected in only 1 of 40 normal pancreas tissues.

Many genes involved in cell adhesion were also hypermethylated in IPMNs, including members of the cadherin superfamily *CDH2*, *CDH4*, *PCDH7*, *PCDH8*, *PCDH10*, *PCDH17*, and *PCDHB7*. Loss of the protein product of *CDH2* (n-cadherin) expression has been reported in infiltrating pancreatic ductal adenocarcinomas (46). We and others have previously reported occasional silencing, mutation, and focal loss of expression of *CDH1/E-cadherin* in pancreatic cancers (47, 48). Interestingly, occasional somatic mutations of cadherins and protocadherins have been identified in pancreatic cancers (45).

In summary, genome-wide CpG island methylation profiling of IPMNs reveals that IPMNs harbor aberrant methylation of hundreds of CpG islands relative to normal pancreatic duct and that aberrant CpG island methylation increases with IPMN grade. The specificity of methylation of genes such as *BNIP3* for high-grade dysplasia highlights the potential diagnostic applications of methylated genes in the evaluation of IPMNs.

References

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA Cancer J Clin* 2011;61:212–36.
2. Goggins M. Markers of pancreatic cancer: working toward early detection. *Clin Cancer Res* 2011;17:635–7.
3. Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. *Clin Gastroenterol Hepatol* 2006;4:766–81; quiz 665.
4. Laffan TA, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S, et al. Prevalence of unsuspected pancreatic cysts on MDCT. *AJR Am J Roentgenol* 2008;191:802–7.
5. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. *Am J Surg Pathol* 2004;28:977–87.
6. Winter JM, Cameron JL, Lillemoie KD, Campbell KA, Chang D, Riall TS, et al. Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis. *Ann Surg* 2006;243:673–80; discussion 80–3.
7. Vincent A, Herman JM, Schulick R, Hruban R, Goggins M. Pancreatic cancer. *Lancet* 2011;378:607–20.
8. Hruban RH, Maitra A, Kern SE, Goggins M. Precursors to pancreatic cancer. *Gastroenterol Clin North Am* 2007;36:831–49.
9. Terris B, Blaveri E, Cmgorac-Jurcevic T, Jones M, Missiaglia E, Ruzsniowski P, et al. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. *Am J Pathol* 2002;160:1745–54.
10. Sato N, Fukushima N, Maitra A, Iacobuzio-Donahue CA, van Heek NT, Cameron JL, et al. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. *Am J Pathol* 2004;164:903–14.
11. Sessa F, Solcia E, Capella C, Bonato M, Scarpa A, Zamboni G, et al. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. *Virchows Arch* 1994;425:357–67.
12. Sato N, Rosty C, Jansen M, Fukushima N, Ueki T, Yeo CJ, et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. *Am J Pathol* 2001;159:2017–22.
13. Schonleben F, Qiu W, Ciau NT, Ho DJ, Li X, Allendorf JD, et al. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. *Clin Cancer Res* 2006;12:3851–5.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Lillian Dasko-Vincent of Cell Imaging Core Facility, Sidney Kimmel Comprehensive Cancer Center, and Dante Trusty of Department of Pathology for their technical support.

Grant Support

This work was supported by NIH grants (P50-CA62924, R01-CA120432, R01-CA97075) and the Michael Rolfe Foundation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 4, 2011; revised November 19, 2011; accepted December 5, 2011; published OnlineFirst December 15, 2011.

14. Abe T, Fukushima N, Brune K, Boehm CSN, Matsubayashi H, Canto M, et al. Genome wide allelotypes of familial pancreatic adenocarcinomas and familial and sporadic intraductal papillary mucinous neoplasms. *Clin Cancer Res* 2007;13:6019–25.
15. Biankin AV, Kench JG, Biankin SA, Lee CS, Morey AL, Dijkman FP, et al. Pancreatic intraepithelial neoplasia in association with intraductal papillary mucinous neoplasms of the pancreas: implications for disease progression and recurrence. *Am J Surg Pathol* 2004;28:1184–92.
16. Moriya T, Kimura W, Semba S, Sakurai F, Hirai I, Ma J, et al. Biological similarities and differences between pancreatic intraepithelial neoplasias and intraductal papillary mucinous neoplasms. *Int J Gastrointest Cancer* 2005;35:111–9.
17. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. *Cancer Res* 2003;63:3735–42.
18. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR, et al. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. *Oncogene* 2005;24:850–8.
19. Jansen M, Fukushima N, Rosty C, Walter K, Altink R, Heek TV, et al. Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanINs. *Cancer Biol Ther* 2002;1:293–6.
20. Sato N, Fukushima N, Chang R, Matsubayashi H, Goggins M. Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. *Gastroenterology* 2006;130:548–65.
21. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. *Oncogene* 2003;22:5021–30.
22. House MG, Guo M, Iacobuzio-Donahue C, Herman JG. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. *Carcinogenesis* 2003;24:193–8.
23. Sato N, Ueki T, Fukushima N, Iacobuzio-Donahue CA, Yeo CJ, Cameron JL, et al. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. *Gastroenterology* 2002;123:365–72.
24. Hong SM, Kelly D, Griffith M, Omura N, Li A, Li CP, et al. Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. *Mod Pathol* 2008;21:1499–507.

25. Longnecker DS, Adsay NV, Fernandez-del Castillo C, Hruban RH, Kasugai T, Klimstra DS, et al. Histopathological diagnosis of pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms: interobserver agreement. *Pancreas* 2005;31:344–9.
26. Hruban RH, Pitman MB, Klimstra DS. Tumors of the pancreas. AFIP atlas of tumor pathology series 4. Washington, DC: American Registry of Pathology and American Forces Institute of Pathology; 2007.
27. Furukawa T, Kloppel G, Volkan Adsay N, Albores-Saavedra J, Fukushima N, Horii A, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. *Virchows Arch* 2005;447:794–9.
28. Andrejevic-Blant S, Kosmahl M, Sipos B, Kloppel G. Pancreatic intraductal papillary-mucinous neoplasms: a new and evolving entity. *Virchows Arch* 2007;451:863–9.
29. Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. 4th ed. Lyon, France: IARC; 2010.
30. Omura N, Li CP, Li A, Hong SM, Walter K, Jimeno A, et al. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. *Cancer Biol Ther* 2008;7:1146–56.
31. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc Natl Acad Sci U S A* 1996;93:9821–6.
32. Koorstra JB, Hong SM, Shi C, Meeker AK, Ryu JK, Offerhaus GJ, et al. Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia. *Mod Pathol* 2009;22:1439–45.
33. Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, Solomon A, et al. Characterizing DNA methylation patterns in pancreatic cancer genome. *Mol Oncol* 2009;3:425–38.
34. Vincent A, Omura N, Hong SM, Jaffe A, Eshleman J, Goggins M. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. *Clin Cancer Res* 2011;17:4341–54.
35. Okami J, Simeone DM, Logsdon CD. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. *Cancer Res* 2004;64:5338–46.
36. Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. *Pancreatol* 2006;6:17–32.
37. Matsubayashi H, Canto M, Sato N, Klein A, Abe T, Yamashita K, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. *Cancer Res* 2006;66:1208–17.
38. Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. *Clin Gastroenterol Hepatol* 2004;2:606–21.
39. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? *Nat Rev Cancer* 2002;2:777–85.
40. Lioubinski O, Muller M, Wegner M, Sander M. Expression of Sox transcription factors in the developing mouse pancreas. *Dev Dyn* 2003;227:402–8.
41. Zhang W, Glockner SC, Guo M, Machida EO, Wang DH, Easwaran H, et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. *Cancer Res* 2008;68:2764–72.
42. Du YC, Oshima H, Oguma K, Kitamura T, Itadani H, Fujimura T, et al. Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. *Gastroenterology* 2009;137:1346–57.
43. Zardo G, Tiirikainen MI, Hong C, Misra A, Feuerstein BG, Volik S, et al. Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. *Nat Genet* 2002;32:453–8.
44. Zhao LY, Niu Y, Santiago A, Liu J, Albert SH, Robertson KD, et al. An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis. *Cancer Res* 2006;66:9445–52.
45. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008;321:1801–6.
46. Cates JM, Byrd RH, Fohn LE, Tatsas AD, Washington MK, Black CC. Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma. *Pancreas* 2009;38:e1–6.
47. Hong SM, Li A, Olino K, Wolfgang CL, Herman JM, Schulick RD, et al. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. *Mod Pathol* 2011;24:1237–47.
48. Li A, Omura N, Hong SM, Vincent A, Walter K, Griffith M, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. *Cancer Res* 2010;70:5226–37.